Trial · NCT07574723
Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity
NCT07574723, Not applicable, Recruiting, Dasman Diabetes Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity. Trials, record NCT07574723. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07574723
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity
- NCT number
- NCT07574723
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 68 participants, estimated
- Lead sponsor
- Dasman Diabetes Institute
- Conditions
- Obesity
- Interventions
- Tirzepatide (Per-label titration), Tirzepatide (Flexible titration)
- First posted
- 2026-05-08
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to discontinuation of the treatment regimen | Randomization to Week 76 | Time from randomization to permanent discontinuation of the assigned tirzepatide titration regimen due to adverse events. Analyzed as restricted mean time on treatment (RMST), estimated as the area under the Kaplan-Meier curve up to 76 weeks and reported in weeks. Participants remaining on treatment at Week 76 are censored at that time. Higher values indicate longer time on treatment (better outcome). |
| Secondary | Exposure-adjusted rate of vomiting episodes assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR) | Baseline to Week 76 | Vomiting is assessed weekly using the validated M-INVR. The vomiting component is scored from 0 (no vomiting) to 4 (severe or frequent vomiting), with higher scores indicating worse outcomes. Vomiting burden will be summarized as weekly vomiting severity scores and as an exposure-adjusted rate (episodes per patient-week), calculated as the total number of vomiting episodes divided by each participant's total follow-up time |
| Secondary | Incidence, frequency, and duration of vomiting assessed using the MASCC Antiemesis Tool - Modified Index of Nausea and Vomiting (M-INVR) | Baseline to Week 76 | Vomiting is assessed weekly using the MASCC Antiemesis Tool - Modified Index of Nausea and Vomiting (M-INVR), a validated patient-reported outcome measure. The vomiting subscale score is calculated as the sum of relevant vomiting items, with scores ranging from 0 to 16, where higher scores indicate greater incidence, frequency, and duration of vomiting (worse outcome). |
| Secondary | Change in body weight | Baseline to Week 76 | Absolute and percentage change in body weight from baseline. |
| Secondary | Proportion of participants remaining on active study medication | Week 76 | Number of participants continuing to receive active study medication at the end of the trial. |
| Secondary | Change in glycated hemoglobin (HbA1c) | Baseline to Week 76 | Change in HbA1c from baseline. |
| Secondary | Change in lean body mass assessed by dual-energy X-ray absorptiometry (DEXA) | Baseline to Week 76 | Change in total lean body mass measured by dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Change in visceral adiposity assessed by dual-energy X-ray absorptiometry (DEXA) | Baseline to Week 76 | Change in visceral adipose tissue measured by dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Change in fat body mass assessed by dual-energy X-ray absorptiometry (DEXA) | Baseline to Week 76 | Change in total fat body mass measured by dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Change in Alanine Aminotransferase (ALT) | Baseline to Week 76 | Change from baseline in serum alanine aminotransferase (ALT) levels in U/L, measured using standard laboratory methods. |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07574723
GET https://conductscience.org/api/trials/v1/NCT07574723/registered?page=2